CN102526003B - New application of tetrahydrocurcumin - Google Patents
New application of tetrahydrocurcumin Download PDFInfo
- Publication number
- CN102526003B CN102526003B CN201210034468.3A CN201210034468A CN102526003B CN 102526003 B CN102526003 B CN 102526003B CN 201210034468 A CN201210034468 A CN 201210034468A CN 102526003 B CN102526003 B CN 102526003B
- Authority
- CN
- China
- Prior art keywords
- tetrahydrocurcumin
- group
- thc
- blood
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides an application of tetrahydrocurcumin in preparation of medicaments for preventing or/and treating hypertension. The invention further provides a medicinal composition for preventing or/and treating the hypertension. The tetrahydrocurcumin has the effects of reducing weight, fasting blood-glucose, triglyceride and cholesterol as well as blood pressure for experimental metabolic syndrome rats.
Description
The application is application number: the dividing an application of 201010100518.4 patent application.Original application application number: 201010100518.4, the applying date: on January 25th, 2010, denomination of invention: the new purposes of tetrahydrocurcumin.
Technical field
The present invention relates to the new purposes of tetrahydrocurcumin, particularly, be in preparation prevention or/and treat the purposes in hypertensive medicine.
Background technology
About metabolism syndrome (Metabolic Syndrome, MS) there is no in the world unified, generally acknowledged definition at present, it is generally acknowledged, MS is that take diabetes or IGR, hypertension, dyslipidemia, the central obesity by polygenes and multiple environmental factors comprehensive function is main Connotation, take insulin resistant as common pathologic basis, and the multiple metabolic disease of take is assembled one group of clinical syndrome that has a strong impact on human health as clinical characters.At present nearly 1/4～1/3 adult in the whole world is subject to the impact of MS, popular along with aged tendency of population and Overweight-obesity, and its sickness rate and prevalence increase year by year, and the MS prevalence of the 20Nian Nei， U.S. in the past rises to 39% from 21%.The prevalence situation of MS China is that northern resident's prevalence is higher than southern resident, urbanite is higher than urban residents, 2000 Nian～calendar year 2001 China suffer from MS for 35～74 years old number in adult has risen to 7,700 ten thousand (16.5%), and increases with the age.Guide (NCEP-ATP III), in April, 2004, Chinese Medical Association's diabetology branch etc. all made regulation to the definition of metabolism syndrome and diagnostic criteria to 1999 NianWHO, calendar year 2001 U.S. cholesterol education plan adult treatment groups for the third time, but there is no the diagnostic criteria of unanimously generally acknowledging and be applicable to various crowds.For this reason, on the basis being defined at WHO and ATP-III by international multidigit expert IDF (IDF) in April, 2005, to MS, diagnostic criteria is reached common understanding and has been promulgated that IDF knows together about the whole world of metabolism syndrome.IDF newly defines: confirm whether body is metabolism syndrome one by one, must possess: (1) central obesity: in European descendants' ethnic group, be defined as male waistline >=94cm, women waistline >=80cm adopts ethnic specific waistline point of contact in other ethnic groups.(2) separately add in following 4 factors any two: 1. triglyceride (TG) level raises: > 150mg/dl (1.7mmol/L), or accepted the special treatment for this dyslipidemias; 2. HDL-C level reduces: male < 40mg/dl (1.03mmol/L), women < 50mg/dl (1.29mmol/L) or accepted the special treatment for this dyslipidemias; 3. hypertension: systolic pressure >=130mmHg or diastolic pressure >=85mmHg, or be diagnosed as hypertension before this and received treatment; 4. fasting glucose raises: fasting glucose >=100mg/dl (5.6mmol/L), or be diagnosed as type 2 diabetes mellitus.Available data thinks that obese type type 2 diabetes mellitus belongs to a kind of specific type of metabolism syndrome, and the mechanism for the treatment of obese type type 2 diabetes mellitus it be unclear that, and follows fat type 2 diabetes mellitus not to be equal to the type 2 diabetes mellitus on ordinary meaning.Insulin resistant and defect of insulin secretion are type 2 diabetes mellitus pathogenesis basis, although initial stage beta Cell of islet can compensatory insulin resistant, it is normal that blood sugar concentration still can maintain, but when blood sugar increasing that body can not compensatoryly be caused by insulin resistant, blood glucose continued higher than normal range, finally caused type 2 diabetes mellitus to occur.Insulin resistant is the key factor through the whole generation evolution of type 2 diabetes mellitus, this process in Type 2 Diabetes Mellitus Patients with Obesity performance obviously, but not Type 2 Diabetes Mellitus Patients with Obesity is not obvious, fat also different to the reaction of antidiabetic drug from nonobese type 2 diabetes mellitus patient.(Guo Kaixia, etc., fat and the comparison of nonobese type 2 diabetes mellitus patient glucose-lowering treatment effect, practical medical magazine, the 26th the 05th phase of volume of May in 2009), therefore, the medicine that conventionally can be used for treating type 2 diabetes mellitus might not just can be treated obese type type 2 diabetes mellitus.
Clinical treatment MS primary and foremost purpose is to reduce the cardiopathic risks and assumptions of atherogenicity and prevention type 2 diabetes mellitus, mainly to reduce LDL-c, control hypertension, diabetes, emphatically from treatment property improvement life style (mainly comprising that taking in heat controls with nutritional labeling, reduces body weight and increases motion), control every metabolic risk factors (treatment of tune fat, regulating and controlling blood sugar, strictly control hypertension, high blood clotting, microalbuminuria, hyperuricemia and various inflammatory factor, weight reduction with drugs etc.) two aspects comprehensively and set about.Although the mode of making the life better is considered to the first-selected measure of MS early intervention, Drug therapy is still essential means for the not good and high-risk cardiovascular patient of those life style intervention effects.The medicine for the treatment of MS mainly contains: hypoglycemic medicine, oral fat regulation medicine, enalapril meleate, oral uric acid resisting medicine, oral weight reduction medicine, oral vasoactive agent etc.Have report Rimonabant by the antagonism to Cannabined receptor 1 (CB1), suppress endocannabinoid system (EC system), performance appetite-suppressing, minimizing are ingested, slimming effect.Ongoing III phase clinical research result shows, in obese patient, rimonabant not only can lose weight, and can also effectively reduce blood glucose, reduce blood pressure, regulates blood fat, contribute to patient to give up smoking and prevent the body weight after smoking cessation to increase, thereby reaching the object of integrated control MS.Therefore, rimonabant is considered to the medicine of a kind of control MS very likely.Research shows, oxidation of Chinese herb drug puerarin, sesamin, three-hypers tea one-tenth such as (be grouped into) Folium Camelliae sinensis, Folium Ilicis, Folium Mori, Flos Chrysanthemi, Semen Cassiaes, capsule for treating diabetes and nephrodystrophy (Radix Ginseng, the Radix Astragali, Radix Et Rhizoma Rhei, Hirudo, Rhizoma Coptidis, Polyporus form) etc. can improve insulin resistant and the lipid metabolism of rats with metabolic syndrome model, have the effect that delays metabolism syndrome process.
Up to the present, also do not have a kind of medicine can reach by life-time service the object of all pathological changes for the treatment of MS.Can only take to treat respectively at present the method for each pathological changes, as combined, adopt treatments such as adjusting blood fat, blood pressure lowering and blood sugar lowering.Therefore the medicine that, can simultaneously effectively correct the disorderly factor of MS various clinical becomes the focus of research recently.
Curcumin Curcumin, chemical name:
1,6-Heptadiene-3,5-dione, 1,7-bis (4-hydroxy-3-methoxyphenyl)-, molecular formula: C
21h
20o
6; Molecular weight: 368.37, structural formula is:
For orange-yellow crystalline powder, 183 ° of fusing points.Water insoluble and ether, is dissolved in ethanol and glacial acetic acid.There is function of gallbladder promoting, it is antibiotic that (staphylococcus aureus is had to stronger antibacterial effect, and Detoxication, can derive from Zingiberaceae various plants.Tao Zhengxian, etc., the impact of curcumin on rats with metabolic syndrome ICAM-1 and related serological index, Journal of the Fourth Military Medical University, 2006; 27 (24), Zhao Huijuan, etc., the impact of curcumin on rats with metabolic syndrome Plasma TNF-α and Serum sICAM-1, Chinese rehabilitation medicine magazine, 2006 years, the 21st volume, the 7th phase; Shi Lei, the impact of curcumin on type 2 diabetes mellitus rat blood sugar, Hebei medical science, the 14th the 10th phase of volume of October in 2008, has all reported the purposes of curcumin.
Tetrahydrocurcumin is one of main metabolites of curcumin, and structure is as shown below:
Tetrahydrocurcumin (Tetrahydrocurcumin, THC) CAS NO.:36062-04-1
According to bibliographical information, the two the pharmacological action of tetrahydrocurcumin and curcumin is different.After tetrahydrocurcumin Mulberry Extract, self can be degraded into again 2-methoxyl group o-hydroxy group propionic acid compounds, and this compound is very strong antioxidant equally, so tetrahydrocurcumin has double anti-oxidative defense mechanism, tetrahydrocurcumin class shows the biological activity stronger than curcumin.And tetrahydrocurcumin water solublity, stability are all good than curcumin.Be mainly used at present cosmetics brightening agent, the additive in antisenescence health product and appetrol.The report of tetrahydrocurcumin is less at present, as number of patent application: 200680016918.9, denomination of invention: use the personal care composition that comprises tetrahydrocurcumin to regulate mammiferous collenchyme, this invention provides personal care composition, described compositions comprises independent tetrahydrocurcumin, or the combination that comprises tetrahydrocurcumin and tetrahydrochysene demethoxycurcumin and/or tetrahydrochysene bisdemethoxycurcumin.The present invention also provides the method that regulates mammiferous keratinous tissue conditions by personal care composition described in local application.Application number: 200810010039.6 novel tetrahydro curcumin derivatives and salt, the invention belongs to medical technical field, be the novel tetrahydro curcumin derivatives of a class---tetrahydrocurcumin Mannich base derivant and its esters.The general structure of this compounds is I: wherein: R1 group representative: alkyl or replacement or unsubstituted aralkyl; The representative of R2 group: (1) hydrogen, (2) fatty primary secondary amine methylene, (3) replace or unsubstituted ring-shaped fat secondary amine methylene; The representative of R3 group: (1) hydrogen, (2) fatty primary secondary amine methylene, (3) replace or unsubstituted ring-shaped fat secondary amine methylene.Its esters comprises the salt that hydrochlorate, hydrobromate, methane sulfonates and other can be medicinal.Compound of the present invention has anticancer significantly, antioxidation, the pharmacologically active of elimination free radical and inhibition microglial activation.Application number: 200810070804.3, denomination of invention: tetrahydrocurcumin, for the preparation of the purposes of antidepressants and the preparation method of solid dispersion thereof, the present invention relates to tetrahydrocurcumin for the preparation of the purposes of antidepressants and a kind of preparation method of tetrahydrocurcumin solid dispersion.The object of the present invention is to provide tetrahydrocurcumin for the preparation of the application of antidepressants.Tetrahydrocurcumin solid dispersion, is prepared into solid dispersion by a certain percentage with tetrahydrocurcumin and surfactant.Its preparation method is: the tetrahydrocurcumin and the surfactant that by mass ratio, are 1: 3～1: 30 are heated to, after complete melting, be placed in low temperature environment freezing, then takes out and dries, and pulverizes, and obtains tetrahydrocurcumin solid dispersion.Tetrahydrocurcumin and solid dispersion thereof are for the preparation of the application of antidepressant medicine, health product, food or food additive.Tetrahydrocurcumin has antidepressant effect, and its effect performance may be with to affect monoamine neurotransmitter system relevant, and in addition, with fluoxetine comparison, tetrahydrocurcumin has low, the eutherapeutic advantage of toxicity.The tetrahydrocurcumin rat diabetes model due to streptozotocin that studies show that of Pari etc. has antioxidation (Life Sciences 79 (2006) 1720-1728); Tetrahydrocurcumin is rat model of type 2 diabetes mellitus model due to streptozotocin, can reduce the level of blood plasma glycated protein, sialic level in rising plasma insulin and tissue, and hexose, hexosamine and fucose maintain normally (Plant Foods for HumanNutrition 62:25-29,2007) in tissue; Rat Model of Type 2 Diabetes cell membrane Insulin receptor INSR binding site number due to tetrahydrocurcumin can increase, thus (J.Biosci.33 (1), March 2008,63-72) for rising plasma insulin content.Patumraj etc. studies show that, tetrahydrocurcumin can significantly improve experimental diabetic rats model vessel endothelial dysfunction (AfricanJournal of Biochemistry Research Vol.3 (5) due to streptozotocin, pp.259-265, May, 2009).
At present still there is no tetrahydrocurcumin for preventing or/and treat the relevant report of metabolism syndrome, do not report that tetrahydrocurcumin can be used for treating obese type type 2 diabetes mellitus yet.
Summary of the invention
Technical scheme of the present invention has been to provide the new purposes of tetrahydrocurcumin.Another technical scheme of the present invention has been to provide a kind of prevention or/and treat hypertensive pharmaceutical composition.
The invention provides tetrahydrocurcumin prevents or/and the purposes in the medicine for the treatment of metabolism syndrome (metabolicsyndrome, MS) in preparation.
Wherein, described metabolism syndrome is that one group of multiple Developmental and Metabolic Disorder such as obesity, hypertension, dyslipidemia, abnormal carbohydrate metabolism is one group of clinical syndrome of feature in individuality gathering.
Wherein, described medicine is that prevention is or/and the medicine of the multiple Developmental and Metabolic Disorder such as the obesity that treatment metabolism syndrome relates to, hypertension, dyslipidemia, abnormal carbohydrate metabolism (diabetes or IGR).
Wherein, described medicine is that prevention is or/and the medicine of the obesity that treatment obese type type 2 diabetes mellitus relates to, dyslipidemia, abnormal carbohydrate metabolism (diabetes or IGR).
Wherein, described medicine can, by correcting insulin resistant, effectively be corrected the disorderly factor of MS various clinical simultaneously.
Wherein, described medicine is that prevention is or/and treat fat medicine.Described medicine is that prevention is or/and treat hypertensive medicine.Described medicine is that prevention is or/and the medicine for the treatment of hyperlipidemia.
A kind of prevention is also provided in the present invention or/and the pharmaceutical composition for the treatment of metabolism syndrome, and it is that tetrahydrocurcumin by effective dose is active component, adds the medicament that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
Wherein, described medicament is oral formulations or ejection preparation.
Medicine of the present invention is used for prevention or/and treatment metabolism syndrome, can be used for prevention or/and one group of multiple Developmental and Metabolic Disorder such as treatment obesity, hypertension, dyslipidemia, abnormal carbohydrate metabolism is assembled the medicine for one group of clinical syndrome of feature at individuality, drug effect is clear and definite, is the new clinically medicine that can effectively correct MS various clinical disorder factor simultaneously.
Tetrahydrocurcumin has the effect that reduces body weight, reduction fasting glucose, reduction triglyceride and T-CHOL, reduces blood pressure to Experimental Metabolic Syndrome rat.
Obviously, according to foregoing of the present invention, according to ordinary skill knowledge and the customary means of this area, not departing under the above-mentioned basic fundamental thought of the present invention prerequisite, can also make modification, replacement or the change of other various ways.
The specific embodiment of form, is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Accompanying drawing explanation
Fig. 1 tetrahydrocurcumin compounds synthetic route chart
The specific embodiment
Be embodiment of the present invention below, it is only the invention process illustration, and can not be interpreted as and limit the scope of the invention.
The preparation of embodiment 1 tetrahydrocurcumin compounds
By realize the synthetic of the various derivants of tetrahydrocurcumin (sulfonate of the different guarantors of two keys and degree Rhizoma Curcumae Longae diphenyl hydro carbons in heptan, relevant glucuronide conjugate, glucuronide conjugate etc.) as the synthetic route of Fig. 1.This process relates to three key issues: the selectivity during various polysubstituted aldehyde is synthetic; Ethyl acetoacetate and full reducedly close rear selective deprotecting; The selection of hydrogenation position during curcumin analogue transforms to various degree hydrogenated products.Owing to having found in past research that method and the polysubstituted method of aromatic aldehyde that the sour selectivity of Lewis is deviate from aromatic ring hydroxyl protecting group have multiple choices, first and second key issue can solve has multiple selective means.As for the 3rd problem, can realize or control the degree of reduction, the position of reduction by the reduction in different phase or the selection by different reducing agents.
The effect of embodiment 2 tetrahydrocurcumin (THC) to normal mouse appetite, body weight, blood glucose and blood fat
KM mice adaptability is fed after 3 days and is tested.60 mices are divided into 5 groups by fasting blood sugar stratified random, 12 every group.If Normal group, tri-dosage groups (5 of THC, 15,50mg/Kg), positive controls (glibenclamide 25mg/Kg), each group all adopts to wait holds not isoconcentration ig administration (Normal group gives isometric(al) 0.5% sodium carboxymethyl cellulose), tri-concentration of THC are respectively 0.05%, 0.15%, 0.5%; Positive drug concentration 0.25%.Once a day, regularly administration, continuous 5 days.Observation index and detection method: 1. body weight (BW) before administration and after administration the 5th day set time measure; 2. food-intake (FI) decrement method is measured, every day 1 time; Fasting glucose (FBG) before administration and after administration the 5th day set time measure.Method: cut tail after mice fasting 4h (freely drinking water) and get blood, measure with 5 seconds blood glucose monitoring systems of happy one-tenth and 5 seconds blood glucose strips; 4. triglyceride (TG) and T-CHOL (T-CHO) administration are plucked eyeball in 5 days and are got blood after fasting 4h, and separation of serum, measures with automatic clinical chemistry analyzer; 5. insulin (INS) administration is plucked eyeball in 5 days and is got blood after fasting 4h, and separation of serum is measured by test kit requirement with putting the method for exempting from; 6. the inverse of insulin sensitivity index fasting glucose and fasting insulin product, then get natural logrithm.Result with
represent, with PEMS3.1 statistical package, add up, between group, relatively with t check, during heterogeneity of variance, t ' checks, inspection level α=0.05.
From table 1-table 5, THC has the effect that reduces food-intake, reduction body weight, reduces fasting glucose, reduction triglyceride and T-CHOL to normal KM mice, and to normal mouse islets element, secretion has no significant effect.
The impact of table 1.THC on normal Mouse Weight
With normal group comparison: * P < 0.05, * * P < 0.01, lower same.
The impact of table 2.THC on normal mouse food-intake
The impact of table 3.THC on normal mouse fasting glucose
The impact of table 4.THC on normal mouse triglyceride and T-CHOL
| Group | Dosage (mg/kg) | TC(mmol/L) | TG(mmol/L) |
| Normal group | 2.38±0.34 | 1.16±0.29 | |
| THC group | 5 | 2.33±0.31 | 0.87±0.14 ＊ |
| THC group | 15 | 2.05±0.30 ＊ | 0.79±0.12 ＊ |
| THC group | 50 | 1.81±0.43 ＊＊ | 0.68±0.17 ＊＊ |
the impact of table 5.THC on normal mouse islets element and insulin sensitivity index
| Group | Dosage (mg/kg) | INS(mlU/L) | Sensitivity Index |
| Normal group | 13.2±3.2 | -4.6±0.3 | |
| THC group | 5 | 13.6±2.8 | -4.3±0.4 |
| THC group | 15 | 13.4±4.0 | -4.6±0.3 |
| THC group | 50 | 12.8±4.9 | -4.5±0.3 |
The effect of embodiment 3 tetrahydrocurcumin (THC) to Experimental Metabolic Syndrome rat
SD rat adaptability is fed after 7 days and is tested.80 rats are divided into 2 groups at random by body weight: 10 of Normal groups, 70 of modeling groups.Normal group is filled with 4% tween 80, and modeling group is filled with fat milk (formula: Adeps Sus domestica 20%, cholesterol 4%, cholate 1%, white sugar 20%, Sal 8%, propylthiouracil 1%, tween 80 4%), gavage volume 1ml/100gBW, qd.After continuous 6 weeks, rat fasting 16h, modeling group lumbar injection STZ 30mg/kg is (with pH4.2, the citrate buffer solution preparation of 0.1mol/L, lucifuge ice bath, now with the current), the isopyknic citrate buffer solution of normal group lumbar injection, volume injected 0.5ml/100gBW.After injection STZ, modeling group continues to fill with fat milk, to testing, finishes.Within after injection STZ 1 week, survey fasting glucose, take blood sugar increasing in being the successful standard of modeling, by fasting blood sugar, one-tenth mould rat is divided into 5 groups at random, establishes model control group, tri-dosage groups (5,15 of THC, 30mg/Kg), positive controls (metformin 200mg/Kg), each group all adopts to wait holds not isoconcentration ig administration (Normal group and model control group give isometric(al) 0.5% sodium carboxymethyl cellulose), and tri-concentration of THC are respectively 0.1%, 0.3%, 0.6%; Positive drug concentration 4%.Once a day, regularly administration, continuous 7 days.Observation index and detection method: 1. body weight (BW) is measured before administration and after administration; Fasting glucose (FBG) before administration and after administration 2 weeks and 4 week set time measure.Method: cut tail after rat fasting 6h (freely drinking water) and get blood, measure with 5 seconds blood glucose monitoring systems of happy one-tenth and 5 seconds blood glucose strips; 3. blood fat administration ends at femoral artery blood-letting after fasting 6h, and separation of serum, measures by test kit requirement; Blood pressure (BP) before administration and administration finish with non-invasive blood pressure test macro, to measure afterwards, every rat is surveyed 2～3 times, averages.Result is so that (x ± S represents, adds up with PEMS3.1 statistical package, and between group, relatively with t check, during heterogeneity of variance, t ' checks, inspection level α=0.05.
From table 6-table 9, THC has the effect that reduces body weight, reduction fasting glucose, reduction triglyceride and T-CHOL, reduces blood pressure to Experimental Metabolic Syndrome rat.
Table 6.THC is on the impact of Experimental Metabolic Syndrome rat body weight ((x ± S, n=10)
With model group comparison: * P < 0.05, * * P < 0.01, lower same.
The impact of table 7.THC on Experimental Metabolic Syndrome rat fasting blood-glucose
The impact of table 8.THC on Experimental Metabolic Syndrome rat triglyceride
Impact on Experimental Metabolic Syndrome rat blood pressure before and after table 9.THC administration
Embodiment 4 tetrahydrocurcumin (THC) are to KK-A
ythe effect of mice (spontaneous obese type type ii diabetes mice)
The equal adaptability of all mices is fed after 1 week and is tested.10 C57 mices are as Normal group.50 KK-A
ymice by sky take blood glucose value be divided at random model control group, positive controls (glibenclamide 25mg/kg) and tri-dosage groups of THC (100,200,400mg/kg) 5 groups, 10 every group.Each group adopts not isoconcentration ig administration of isometric(al) (Normal group and model control group give isometric(al) 0.5% sodium carboxymethyl cellulose), and be regularly administered once every day, continuous 28 days.Observation index and detection method: 1. body weight (BW) before administration and after administration weekly the set time measure, 1 time weekly; Fasting glucose (FBG) before administration and after administration weekly the set time measure, 1 time weekly.Method: cut tail after mice fasting 3h (freely drinking water) and get blood, measure with 5 seconds blood glucose monitoring systems of the happy one-tenth in Beijing and 5 seconds blood glucose strips; 3. carbohydrate tolerance (OGTT) is measured in administration on the 21st day.Method: the first fasting 3h (freely drinking water) of mice, cut tail and get blood survey blood glucose (while being zero), then give mouse gavaging glucose 2.5g/kg, measure and fill with sugar rear 0.5,1, the blood glucose value of 2h, and area (AUC) under calculated curve, AUC=0.5* fasting glucose+0.5h blood glucose+1.5*1h blood glucose+2h blood glucose; 4. blood fat administration is plucked eyeball in 28 days and is got blood after fasting 3h measures blood glucose, separation of serum, detect triglyceride (TG), T-CHOL (T-CHO), HDL-C (HDL-C) and low-density lipoprotein cholesterol (LDL-C), with automatic clinical chemistry analyzer, by test kit requirement, measure; 5. the same blood fat of fasting insulin (FINS) blood extracting method, measures by test kit requirement with putting the method for exempting from; 6. insulin sensitivity index (ISI) sky takes blood glucose and the empty inverse that takes insulin product, then gets natural logrithm; 7. fat weight and fat index administration are got abdominal cavity fat (by omentum majus, kidney week, epididymis) and subcutaneous fat (groin) is weighed after 28 days, and calculate abdominal cavity and subcutaneous fat index.Result with
represent, with PEMS3.1 statistical package, carry out the t check of each experimental group and model group comparison, t ' check during heterogeneity of variance, inspection level α=0.05.
From table 10-table 15, THC has the effect that reduces body weight, reduction fasting glucose, reduction triglyceride, T-CHOL and low-density lipoprotein cholesterol, high density lipoprotein increasing cholesterol, minimizing carbohydrate tolerance AUC, reduces subcutaneous fat and abdominal cavity fat to spontaneous obese type type 2 diabetes mellitus mice.
Table 10.THC is to KK-A
ythe impact of Mouse Weight
With model group comparison: * P < 0.05, * * P < 0.01, lower same.
Table 11.THC is to KK-A
ythe impact of mice fasting glucose
Table 12.THC is to KK-A
ythe impact of mice serum insulin and insulin sensitivity index
| Group | Dosage (mg/kg) | Insulin ((μ lU/ml)) | Insulin resistance index |
| Normal group | 18.2±5.8 ＊＊ | -4.66±0.32 ＊＊ | |
| Model group | 156.4±30.8 | -7.73±0.45 | |
| THC group | 100 | 155.9±24.5 | -7.53±0.50 |
| THC group | 200 | 128.6±26.7 ＊ | -7.02±0.42 ＊ |
| THC group | 400 | 119.3±22.2 ＊＊ | -6.89±0.43 ＊＊ |
table 13.THC is to KK-A
ythe impact of lipid of mice
| Group | Dosage (mg/kg) | T-CHO | TG | HDL-C | LDL-C |
| Normal group | 2.27±0.13 ＊＊ | 0.74±0.05 ＊＊ | 2.00±0.13 ＊＊ | 0.16±0.02 ＊＊ | |
| Model group | 4.49±0.33 | 1.46±0.26 | 3.60±0.40 | 0.58±0.06 | |
| THC group | 100 | 4.44±0.45 | 1.36±0.29 | 3.87±0.41 | 0.56±0.14 |
| THC group | 200 | 3.96±0.39 ＊ | 1.21±0.21 ＊ | 4.13±0.36 ＊ | 0.42±0.14 ＊ |
| THC group | 400 | 3.45±0.36 ＊＊ | 1.09±0.24 ＊＊ | 4.58±0.37 ＊＊ | 0.36±0.11 ＊＊ |
Table 14.THC is to KK-A
ythe impact of mice fat and fat index
Table 15.THC is to KK-A
ythe impact of glucose tolerance in mice
In sum, tetrahydrocurcumin of the present invention can be used for prevention or/and treatment metabolism syndrome, can be used for prevention or/and one group of multiple Developmental and Metabolic Disorder such as treatment obesity, hypertension, dyslipidemia, abnormal carbohydrate metabolism is assembled the medicine for one group of clinical syndrome of feature at individuality, and drug effect is clear and definite, can effectively correct the disorderly factor of MS various clinical simultaneously.
Claims (1)
1. tetrahydrocurcumin prevents or/and treat the purposes in hypertensive medicine in preparation as unique active component.
2. purposes according to claim 1, is characterized in that: described medicine is that the tetrahydrocurcumin by effective dose is active component, adds the medicament that pharmaceutically acceptable adjuvant or complementary composition are prepared from.
3. purposes according to claim 2, is characterized in that: described medicament is oral formulations or ejection preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210034468.3A CN102526003B (en) | 2010-01-25 | 2010-01-25 | New application of tetrahydrocurcumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210034468.3A CN102526003B (en) | 2010-01-25 | 2010-01-25 | New application of tetrahydrocurcumin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010100518 Division CN101732292B (en) | 2010-01-25 | 2010-01-25 | Novel application of tetrahydrocurcumin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102526003A CN102526003A (en) | 2012-07-04 |
| CN102526003B true CN102526003B (en) | 2014-02-19 |
Family
ID=46334835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210034468.3A Active CN102526003B (en) | 2010-01-25 | 2010-01-25 | New application of tetrahydrocurcumin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102526003B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2959965A1 (en) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Pharmaceutical formulations comprising tetrahydrocurcumin and lipids |
-
2010
- 2010-01-25 CN CN201210034468.3A patent/CN102526003B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102526003A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6310971B2 (en) | Methods and compositions for treating HIV-related diarrhea | |
| CN101732292B (en) | Novel application of tetrahydrocurcumin | |
| CN109689105A (en) | The combination of FXR agonist | |
| US10172899B2 (en) | Composition for preventing, treating and improving of voiding dysfunction comprising extract from Piper longum L | |
| US20140212524A1 (en) | Methods and compositions to reduce fat gain, promote weight loss in mammals | |
| CN102526003B (en) | New application of tetrahydrocurcumin | |
| CN102552225A (en) | Novel application of tetrahydrocurcumin | |
| CN102526004A (en) | New use of tetrahydrocurcumin | |
| CN109640969A (en) | Subcutaneous injection agent and application thereof for reducing weight | |
| EP2853261B1 (en) | Agent for improving vesicourethral dyssynergia | |
| CN112955132A (en) | Pharmaceutical composition comprising hydroquinone derivative for preventing or treating obesity or non-alcoholic steatohepatitis | |
| CN112007023A (en) | Application of baicalein in preparing medicine for preventing and treating obesity and its complication | |
| CN104906114A (en) | Metformin-gliquidone compound sustained-release capsule and preparation method thereof | |
| EP3332779A1 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
| WO2019201315A1 (en) | Composition containing phlorizin and 1-deoxynojirimycin and use thereof | |
| KR102204204B1 (en) | Composition for treatment of muscular disorders | |
| EP3804705B1 (en) | Pharmaceutical composition for preventing diabetes and use thereof | |
| CN109481424A (en) | Isoliquiritigenin, pharmaceutical composition and its application in treatment diabetic nephropathy | |
| US11850257B2 (en) | Method for enhancing beta-adrenergic response | |
| US20220079975A1 (en) | Method for mitigation of non-alcoholic fatty liver disease by use of a composition comprising small-molecule fucoidan and fucoxanthin | |
| KR101572311B1 (en) | A composition for preventing or treating obesity comprising 2-amino-2-norbornanecarboxylic acid | |
| KR20130075442A (en) | A composition for preventing or treating metabolic syndrome-related diseases | |
| CN106822114B (en) | Application of MTCA in preparation of medicines for reducing blood sugar or blood fat | |
| WO2015192445A1 (en) | Uses of penthorum chinense pursh or extract thereof in preparation of health-care products or medicines for preventing or treating non-alcoholic fatty liver disease | |
| KR101751393B1 (en) | Pharmaceutical composition for the prevention or treatment of muscle loss comprising linoleic acid or pharmaceutically acceptable salts thereof as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |